Search results
Phase III, global, randomised, open-label study
- POSEIDON is a phase III, global, randomised, open-label study with a three-arm design, which evaluated the efficacy of tremelimumab plus durvalumab plus chemotherapy and durvalumab plus chemotherapy versus chemotherapy alone in first-line metastatic NSCLC.
www.esmo.org/oncology-news/adding-tremelimumab-to-durvalumab-and-chemotherapy-provides-survival-benefit-for-patients-with-metastatic-nsclc
People also ask
What is the POSEIDON trial?
Does Poseidon work in metastatic non-small cell lung cancer?
What are updated OS analyses from Poseidon?
Who funded the Poseidon study?
Are there any conflicts of interest in the Poseidon study?
Should Poseidon be a new Me Too strategy?
Feb 20, 2023 · Purpose: The open-label, phase III POSEIDON study evaluated tremelimumab plus durvalumab and chemotherapy (T + D + CT) and durvalumab plus chemotherapy (D + CT) versus chemotherapy alone (CT) in first-line metastatic non-small-cell lung cancer (mNSCLC).
Sep 5, 2024 · In the global, randomized, phase 3 POSEIDON study (NCT03164616), a limited course of tremelimumab plus durvalumab and chemotherapy (T+D+CT) significantly improved OS (hazard ratio [HR] = 0.77, 95% confidence interval [CI]: 0.65–0.92, p = 0.0030; median follow-up 34.9 mo) and progression-free survival (PFS; HR = 0.72, 95% CI: 0.60–0.86, p ...
In the phase 3 POSEIDON study, first-line tremelimumab plus durvalumab and chemotherapy (T + D + CT) significantly improved both progression-free survival (PFS; hazard ratio [HR] 0.72 [95% confidence interval {CI} 0.60-0.86]; P = .0003) and overall survival (OS; HR 0.77 [95% CI 0.65-0.92]; P = .0030) versus chemotherapy alone (CT) in patients ...
May 7, 2021 · POSEIDON was a Phase III trial of AstraZeneca’s Imfinzi (durvalumab) plus platinum-based chemotherapy or Imfinzi, tremelimumab and chemotherapy versus chemotherapy alone in the 1st-line treatment of patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).
Nov 3, 2022 · In the article 6 that accompanies this editorial, the POSEIDON trial demonstrated that dual immunotherapy with durvalumab plus tremelimumab and chemotherapy significantly improved the outcome compared with chemotherapy alone as first-line treatment strategy in advanced non–small-cell lung cancer.
PURPOSE The open-label, phase III POSEIDON study evaluated tremelimumab plus durvalumab and che-motherapy (T D CT) and durvalumab plus chemotherapy (D. 1 1. line metastatic non–small-cell lung cancer (mNSCLC). CT) versus chemotherapy alone (CT) in first- METHODS Patients (n 1,013) with / wild-type mNSCLC were randomly assigned (1:1:1) to.
Nov 15, 2022 · POSEIDON is a phase III, global, randomised, open-label study with a three-arm design, which evaluated the efficacy of tremelimumab plus durvalumab plus chemotherapy and durvalumab plus chemotherapy versus chemotherapy alone in first-line metastatic NSCLC.
